Regulatory Pfizer’s Hympavzi secures FDA expanded indications for haemophilia Pharmaceutical TechnologyPfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B.HematologyRead full story pharminent June 9, 2026 (Last updated: June 9, 2026) Pharmaceutical Technology Pfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1BNext: ADA: AZ reveals oral GLP-1 data in obesity, diabetes Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
